Bart Filius Joins Galapagos as CFO
News Oct 18, 2014
Galapagos NV has announced that Bart Filius, currently Vice President, CFO Sanofi Europe, will join Galapagos as Chief Financial Officer, effective 1 December 2014.
Bart Filius has over 13 years' experience at Sanofi. During the past three years as CFO Sanofi Europe, Bart was instrumental in transforming the Sanofi European organization to be well-positioned beyond the patent cliff.
Earlier at Sanofi, Bart was CFO and Country Manager of Sanofi in the Netherlands. Before that, he was Vice President for Mergers & Acquisitions, during which time Bart led and completed the divestiture of various franchises.
Prior to joining Sanofi, Bart was a strategy consultant at Arthur D. Little. Bart is a Dutch national and has an MBA degree from INSEAD and a bachelor's degree in business from Nyenrode University.
"We are pleased to welcome Bart Filius into our Executive team," said Onno van de Stolpe, CEO of Galapagos. "His vast experience in Big Pharma and his sharp strategic view will help us bring Galapagos to the next level, as we prepare to have our rheumatoid arthritis molecule GLPG0634 enter Phase 3 and progress more programs into patients next year."
"I am very excited to join Galapagos at this important point of its development", said Bart Filius. "As we move forward and the pipeline matures further, I look forward to bringing my experience in Finance and M&A to Galapagos."
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE